Accelerator:
Rhodotron® TT300 HE
Target:
Custom target
Chemistry:
Hardware ready
Process under development
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Actinium-225 is a radioisotope used for treatment in targeted alpha therapy. It has a half-life of 10 days. Clinical trials have demonstrated the applicability of radiopharmaceuticals containing 225Ac to treat various types of cancer including leukaemia, prostate cancer and primary tumours.
Samy Bertrand, Jean-Michel Geets, Cristiana Gameiro, Benoit Nactergal, Jeremy Brison
Willem Leysen, Jakub Damian, Lucia-Ana Popescu, Jasper Mermans, Hanna Skliarova, Dominic Maertens, Stephan Heinitz, Guy Scheveneels, Koen Hasaers, Dennis Elema, Sven Van Den Berghe, Cristiana Gameiro Jean-Michel Geets Samy Bertrand